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Available online 28 September 2006AP-1/cJun, NF-κB and STAT3 transcription factors control expression of numerous genes,
which regulate critical cell functions including proliferation, survival and apoptosis. Sodium
arsenite is known to suppress both the IKK-NF-κB and JAK2-STAT3 signaling pathways and
to activate the MAPK/JNK-cJun pathways, thereby committing some cancers to undergo
apoptosis. Indeed, sodium arsenite is an effective drug for the treatment of acute
promyelocytic leukemia with little nonspecific toxicity. Malignant melanoma is highly
refractory to conventional radio- and chemotherapy. In the present study, we observed
strong effects of sodium arsenite treatment on upregulation of TRAIL-mediated apoptosis in
human and mouse melanomas. Arsenite treatment upregulated surface levels of death
receptors, TRAIL-R1 and TRAIL-R2, through increased translocation of these proteins from
cytoplasm to the cell surface. Furthermore, activation of cJun and suppression of NF-κB by
sodium arsenite resulted in upregulation of the endogenous TRAIL and downregulation of
the cFLIP gene expression (which encodes one of the main anti-apoptotic proteins in
melanomas) followed by cFLIP protein degradation and, finally, by acceleration of TRAIL-
induced apoptosis. Direct suppression of cFLIP expression by cFLIP RNAi also accelerated
TRAIL-induced apoptosis in these melanomas, while COX-2 suppression substantially
increased levels of both TRAIL-induced and arsenite-induced apoptosis. In contrast,
overexpression of permanently active AKTmyr inhibited TRAIL-mediated apoptosis via
downregulation of TRAIL-R1 levels. Finally, AKT overactivation increased melanoma
survival in cell culture and dramatically accelerated growth of melanoma transplant in
vivo, highlighting a role of AKT suppression for effective anticancer treatment.
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Malignantmelanomaremainsoneof themost difficult types of
cancer for successful treatment, and the incidence of mela-
noma has been progressively increasing over the last 40 years
throughout the world [1]. The impairment of apoptosis is one
of the key characteristics of cancer development, which
renders tumors resistant to cytotoxic therapy [2]. Conse-
quently, anticancer drug discovery strategies have focused
on core components of the apoptosis machinery in the cell, as
main targets, in order to restore sensitivity of cancer cells to
apoptosis [3]. In this respect, the use of arsenic trioxide (or
sodium arsenite) as a regulator of gene expression and a
stimulator of oxidative stress, which was followed by induc-
tion of programmed cell death, has been shown to be effective
in the treatment of acute promyelocytic leukemia (APL) [4] and
of prostate cancer cell lines [5]. Arsenic trioxide was approved
by the U.S. Food and Drug Administration for the treatment of
relapsedAPL that is refractory to therapywith all-trans retinoic
acid [Food and Drug Administration (2000), FDA approves
arsenic trioxide for leukemia treatment (http://www.fda.gov/
bbs/topics/ANSWERS/ANS01040.html)]. However, a phase II
trial of arsenic trioxide in patients with metastatic melanoma
was unsuccessful indicating that subsequent clinical trials
should evaluate arsenic in combinationswith other anticancer
drugs that may increase its clinical efficacy [6]. We and others
have recently demonstrated a profound increase in apoptosis
of human melanomas when treated with a combination of
sodium arsenite and an inhibitor of an additional survival
pathway (EGFR, MEK-ERK, PI3K-AKT and COX-2) [7–9] that was
accompanied by the profound increase in cancer cell
apoptosis.
Tumor necrosis factor alpha-related apoptosis-inducing
ligand (TRAIL; APO2L; TNFSF10) is a member of the TNF
superfamily of death receptor ligands and has exhibited great
therapeutic potential against different types of tumors [10].
However, TRAIL is not a universal anticancer agent because
many types of cancer cells still possess resistance to TRAIL.
For human melanoma, cell lines both sensitive and resistant
to TRAIL have been described [11–14]. TRAIL induces the death
signaling cascades by binding one of two cell surface
receptors, TRAIL-R1/DR4/TNFRSF10A or TRAIL-R2/DR5/
TNFRSF10B. Once ligand bound, these receptors assemble a
death-inducing signaling complex (DISC) that contains an
adaptor protein FADD, which recruits the apoptosis-initiating
caspase-8/caspase-10. After processing and activation, these
caspases directly, or through the mitochondrial loop, target
executive caspases [2,15]. In addition, numerous anti-apopto-
tic proteins (such as cFLIP, cIAP1/2, XIAP, survivin, Bcl2 and
BclxL) negatively regulate the development of apoptotic
signaling [2,16]. Differential splicing of cFLIP/CFLAR gene may
produce several isoforms, however, cFLIPL (55-kDa-protein)
and cFLIPS (25 kDa) are the main products. There is a close
structural similarity between cFLIPL and caspase-8; further-
more, cFLIPL binds to caspase-8 at the DISC and can effectively
block its activation [17]. Recent investigations have further
confirmed an anti-apoptotic role of cFLIPL [18,19], although
some other observations indicated that, in certain conditions,
the long form of cFLIP may also support caspase-8 activation[20]. The role of the short form, cFLIPS, as an inhibitor of death
receptor-mediated apoptosis is well established [21].
An additional level for attenuation of TRAIL-mediated
signaling is based on decoy receptors TRAIL-R3 and TRAIL-
R4, which are capable of binding TRAIL but do not transmit
death signals, which decreases the efficiency of apoptosis
induction [10]. Hence, an effective initiation and progression
of the TRAIL/TRAIL-R-mediated signaling in cancer cells
requires: (i) an exogenous ligand (as a recombinant soluble
protein or as a membrane protein on the surface of killer
cells) or an induction of the endogenous surface expression
of TRAIL in the population of target cells; (ii) appropriate
levels of TRAIL-R1/R2 on the cell surface, efficient death
signaling induced by TRAIL-mediated receptor oligomeriza-
tion and the DISC assembling; and (iii) effective repression of
anti-apoptotic protein activities in target cells. This multi-
faceted approach for cancer cell treatment may be achieved
in some cases using combined treatment of soluble recom-
binant TRAIL together with specific inhibitors of cell survival
pathways or with specific suppressors of anti-apoptotic
proteins.
Many human melanomas express different types of death
receptors, such as Fas/APO1, TNF-R1 and TRAIL-R1/R2 (DR4/
DR5) on the cell surface [11–13,22]. Recombinant soluble Fas
ligand (FasL/APO1-L) or agonistic anti-Fas monoclonal anti-
body (mAb) can induce apoptosis in Fas-positive melanomas
with varying efficiency, depending on levels of surface Fas
expression and the effectiveness of death signaling. How-
ever, the strong toxicity of soluble FasL diminishes efficacy of
this treatment for in vivo applications. In contrast, soluble
recombinant TRAIL/APO2-L is relatively nontoxic after sys-
temic treatment as demonstrated in numerous experiments
with different types of tumors in vivo [10], although distinct
recombinant versions of TRAIL demonstrated differential
hepatotoxicity.
In the present study, we have used sodium arsenite as a
modulator of cell signaling pathways to overcome the
resistance of melanoma cell lines to TRAIL. We have demon-
strated strong positive effects of sodium arsenite on TRAIL-
mediated apoptosis of some melanoma lines and have
determined conditions that allow the efficient upregulation
of TRAIL-R levels, induction of the endogenous TRAIL expres-
sion, suppression of anti-apoptotic proteins and development
of TRAIL/TRAIL-R-mediated apoptosis.Methods
Materials
Sodium arsenite and cycloheximide were obtained from
Sigma (St. Louis, MO). Human soluble Fas ligand (recombinant)
and soluble Killer-TRAIL (recombinant) were purchased from
Alexis (San Diego, CA). IKK inhibitor BAY11-7082 and JNK
inhibitor SP600125 were obtained from Biomol (Plymouth
Meeting, PA); MEK inhibitor U0126 and PI3K inhibitor
LY294002 were purchased from Calbiochem (La Jolla, CA).
Caspase inhibitors zVAD-fmk, Ac-IETD-CHO (an inhibitor of
caspase-8 and caspase-6) and Ac-LEHD-CHO (an inhibitor of
caspase-9) were purchased from Calbiochem (La Jolla, CA).
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Human melanoma cell lines LU1205 (also known as 1205lu),
WM793, WM9, WM35, SBCl2 [23] and OM431 as well as mouse
melanoma K1735-SW1 were maintained in a DMEM medium
supplemented with 10% fetal bovine serum (FBS), L-glutamine
and antibiotics. FEMX, LOX and HHMSX human melanoma
lines weremaintained in an RPMI1640medium supplemented
with 10% FBS and antibiotics.
FACS analysis of TRAIL and TRAIL-R1/R2 levels
Surface levels of TRAIL on human and mouse melanomas
were determined by staining with the PE-conjugated anti-
human-TRAIL or anti-mouse-TRAIL mAbs and subsequent
flow cytometry. PE-conjugated mAbs were obtained from
eBioscience (San Diego, CA). Surface levels of TRAIL-R1/DR4
and TRAIL-R2/DR5 were determined by staining with the
corresponding primary mAbs followed by staining with anti-
mouse PE-IgG (BD Biosciences Pharmingen, San Jose, CA). PE-
conjugated nonspecific mouse IgG1 was used as an immu-
noglobulin isotype control. A FACS Calibur flow cytometer
(Becton Dickinson, Mountain View, CA) combined with the
CellQuest program was used to perform flow cytometric
analysis. All experiments were independently repeated 4–5
times.
Transfection and luciferase assay
The NF-κB luciferase reporter containing two κB-binding sites,
Jun2-Luc reporter and empty vector tk-Luc [24], GAS-Luc
reporter containing three repeats of GAS sites from the
Ly6A/E promoter [25] were used to determine NF-κB, AP-1
and STAT transactivation, respectively. Additional reporter
constructs used included 1.5 kb TRAILpr-Luc [26], 1.8 kb TRAIL-
R1pr-Luc [27] and 1 kb cFLIPpr-Luc [28,29]. Transient transfec-
tion of different reporter constructs (1 μg) togetherwith pCMV-
βgal (0.25 μg) into 5×105 melanoma cells was performed using
Lipofectamine (Life Technologies, Invitrogen). Proteins were
prepared for β-Gal and luciferase analysis 16 h after transfec-
tion. Luciferase activity was determined using the Luciferase
assay system (Promega, Madison, WI) and was normalized
based on β-galactosidase levels.
In some experiments, melanoma cells were transfected
with reporter constructs together with certain expression
vectors (ratio 1:3), including pCMV-IκBαΔN [30], pcDNA3-
IKKβS178E/S181E [31], ΔMEKK1 expression vector [32],
pcDNA3-FLAG-MKK7β1 [33], dominant-negative JNK1-APF
[34], dominant-negative form of cJun/TAM67 [35], dominant-
negative STAT3-β [36], dominant-negative STAT3-F and
permanently active STAT3-C [37] in the presence of pCMV-
βGal. Sixteen to 24 h after transfection, luciferase activity was
determined.
Apoptosis studies
Cells were exposed to soluble TRAIL (50 ng/ml) alone or in
combination with cycloheximide (2 μg/mL) or sodium arsenite
(4 μM). Apoptosis was then assessed by quantifying the
percentage of hypodiploid nuclei undergoing DNA fragmenta-tion. Flow cytometric analysis was performed on a FACS
Calibur flow cytometer.
cFLIP and COX-2 suppression by RNAi
The pSUPER retro RNA interference (RNAi) system (Oligoen-
gine, Seattle, WA), which has been utilized for the production
of small RNAi transcripts used to suppress cFLIP and COX-2
expression. Three variants of RNAi of 19 nucleotides designed
to target human COX-2 mRNA and two variants of RNAi to
target human cFLIPwere expressed using vector pSUPER.retro.
puro (pSR-puro). RNAi cFLIP-92 (UGUGGUUCCACCUAAUGUC)
and RNAi COX-2-379 (CCUUCUCUAACCUCUCCUA) were the
most efficient in the corresponding mRNA targeting.
Western blot analysis
Total cell lysates (50–100 μg protein) were resolved on 10%
SDS–PAGE, and processed according to standard protocols.
The antibodies (Abs) used for Western blotting included
monoclonal anti-β-Actin (Sigma); monoclonal anti-Caspase-8
and anti-Caspase-3; (Cell Signaling, Beverly, MA); monoclo-
nal anti-Caspase-3 (procaspase and active forms) (Axxora,
San Diego, CA); monoclonal anti-FLIP (Dave-2); monoclonal
anti-FLIP (NF6) (Axxora, San Diego, CA); monoclonal anti-
XIAP (BD Biosciences, San Jose, CA); monoclonal anti-COX-2
(Cayman Chemical Company, Ann Arbor, Michigan); poly-
clonal Abs to TRAIL (human), TRAIL-R1 and TRAIL-R2/DR5
(Axxora, San Diego, CA); polyclonal Abs against: phospho-
cJun (Ser73) and total cJun; phospho-SAPK/JNK (Thr183/
Tyr185) and JNK; phospho-p44/p42 MAP kinase (Thr202/
Tyr204) and p44/p42 MAP kinase; phospho-p38 MAP kinase
(Thr180/Tyr182) and p38 MAP kinase; phospho-STAT3
(Tyr705) and STAT3; phospho-AKT (Ser473) and AKT; phos-
pho-IκBα (Ser32) and IκBα; PARP (Cell Signaling, Beverly, MA).
Optimal dilutions of primary Abs were 1:1000 to 1:10000. The
secondary Abs (anti-rabbit, anti-mouse or anti-rat) were
conjugated to horseradish peroxidase (dilution 1:5000 to
1:10000); signals were detected using the ECL system
(Amersham, Piscataway, NJ).
EMSA
Electrophoretic mobility shift assay (EMSA) was performed for
the detection of NF-κB DNA-binding activity as previously
described, using the labeled double-strand oligonucleotide
AGCTTGGGGACTTTCCAGCCG (binding site is underlined).
Ubiquitous NF-Y DNA-binding activity was used as an internal
control [7].Results
Induction of cell death in melanomas by treatment with
recombinant TRAIL and sodium arsenite
Since treatment of cancer cells with combined modality is, as
a rule, more effective than monotherapy, our initial aim was
to use different combinations of soluble TRAIL with inhibi-
tors of cell survival pathways to upregulate TRAIL-mediated
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activities of sodium arsenite [7], we decided to elucidate
effects of a combination of TRAIL and sodium arsenite for the
acceleration of apoptosis. First we confirmed that normalFig. 1 – TRAIL induces apoptosis in humanmelanomas. (A) Surf
staining with PE-labeled anti-TRAIL-R1 (DR4) or anti-TRAIL-R2 (D
TRAIL-induced apoptosis in indicated melanoma cell lines. Cells
for indicated time. For apoptosis analysis, cells were stained by PI
as percentage of cells with hypodiploid content of DNA in the pr
mean±SD from three independent experiments. (C) Western blot
form of caspase-3) and PARP cleavage following treatment of WM
sodium arsenite (As, 4 μM) on TRAIL-induced apoptosis in WM9
bars represent mean±SD from three independent experiments.human melanocytes and normal lung fibroblasts are resis-
tant to cytotoxic effects of sodium arsenite at the dose
1–10 μM (data not shown). These are clinically relevant doses
as the arsenic level of 7 μM has been reported in the serum oface expression of TRAIL-R1 and TRAIL-R2 was determined by
R5) mAbs, respectively, and FACS analysis. (B) Kinetics of the
were treated with soluble recombinant TRAIL (50 ng/ml)
24–72 h after treatment. Levels of apoptosis were determined
e-G0/G1 region using flow cytometry. Error bars represent
analysis of caspase-8 and caspase-3 processing (p17 is active
9 melanoma cells with TRAIL (50 ng/ml). (D, E) Effects of
, OM431 and LU1205 cells 24 h and 48 h after treatment. Error
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acute promyelocytic leukemia (APL) [4,38]. In general, we
observed four types of responses in melanomas to sodium
arsenite treatment. Early radial growth phase melanomas
SBCl2 and WM35, similarly to melanocytes, were relatively
resistant to arsenite treatment. Human metastatic melano-
mas LU1205, WM9 and OM431 developed a low-level
apoptosis 24 h after arsenite treatment, which showed
modest increase after 48 h treatment. A vertical growthFig. 2 – Modulation of TRAIL-mediated apoptosis in melanoma c
on TRAIL-induced NF-κB activation (EMSA). The middle “empty”
(B) Western blot analysis of cFLIP levels following treatments of LU
A ratio cFLIPL/Actin is indicated.Monoclonal Ab to FLIP (Dave-2) w
melanoma cell lines. (D and E) Induction of apoptosis in indicate
(50 ng/ml) and CHX (2 μg/ml) have been used. Caspase inhibitors
media 30min before TRAIL+CHX. Cellswere stained by PI 48 h aft
of cells with hypodiploid content of DNA in the pre-G0/G1 region
three independent experiments.phase melanoma WM793 and metastatic melanoma FEMX
were highly sensitive to sodium arsenite due to an induction
of the TNFα-mediated apoptosis that was also accompanied
by the secondary necrosis [7]. In contrast, LOX and HHMSX
metastatic melanomas demonstrated G2/M arrest 24 h after
arsenite treatment, which was accompanied by low-level
apoptosis 48 h after treatment (data not shown). Hence,
arsenite alone at clinically relevant doses (1–10 μM) was not a
universal and efficient inducer of cell death in melanomas.ells. (A) Effect of sodium arsenite pretreatment (4 μM; 30 min)
part of gel-shift has been removed. FP—free labeled probe.
1205 cells with TRAIL (50 ng/ml) and sodium arsenite (4μM).
as used. (C)Western blot analysis of APAF1 and XIAP levels in
d melanoma lines 48 h after indicated treatment. TRAIL
: IETD, LEHD, DEVD, zVAD (20 μM) have been added to the
er treatment. Apoptosis levelswere determined as percentage
using flow cytometry. Error bars represent mean±SD from
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detected on the surface of WM9 and OM431 human melano-
mas (Fig. 1A) and SW1 mouse melanoma cells (data not
shown), in addition to TRAIL receptor-2 (TRAIL-R2/DR5)
detected on the surface of LU1205 (0. 1A), WM9 and WM35
(data not shown) human melanomas. Hence, these cell lines
were potentially susceptible to treatment with exogenous
TRAIL. Indeed, soluble recombinant TRAIL (50 ng/ml) induced
pronounced apoptosis of WM9 melanoma cells 24–48 h after
treatment (Fig. 1B). This was the efficient caspase-8/caspase-
3-dependent apoptosis, which resulted in cleavage of PARP, a
typical target of caspase-3, 6 h after treatment (Fig. 1C).
However, effects of TRAIL on the induction of apoptosis in
LU1205 and OM431 human melanomas and SW1 mouse cells,
which contain modest levels of surface TRAIL-R, were less
pronounced (Fig. 1B). Finally, FEMX human melanoma cells
(R1-negative, R2-positive) only slightly responded to TRAIL
(Figs. 1A, B).
Our next approach was to use a combined treatment of
soluble TRAIL and sodium arsenite for possible acceleration of
apoptosis in melanoma cells. Indeed, sodium arsenite (4 μM)
notably accelerated TRAIL-mediated apoptosis in WM9,
OM431 and LU1205 melanoma cells 24 h after treatment (Fig.
1D). Finally, arsenite substantially increased levels of TRAIL-
induced apoptosis in OM431 and LU1205 human melanoma
cells (Fig. 1E) and in mouse SW1 melanoma cells (data not
shown) 48 h after treatment. At this time point, arsenite
already had no additional effect on acceleration of apoptosis
in TRAIL-sensitive WM9 cells.
Two critical features that may affect TRAIL-induced
apoptosis in the presence of arsenite were (1) downregulation
of basal and TRAIL-induced NF-κB activity and (2) down-
regulation of the NF-κB-dependent targets, including cFLIP
(both long and short forms). A general role of transcription
factor NF-κB in protection against TRAIL-mediated apoptosis
is well known [39,40]. Interestingly, soluble TRAIL (50 ng/ml)
rapidly induced phospho-IκBα degradation in LU1205 mela-
noma cells (data not shown), whichwas accompanied by rapid
induction of NF-κB DNA-binding activity. Pretreatment of
LU1205 cell cultures with sodium arsenite (4 μM, 30 min),
which inhibited IKKβ activation [41], downregulated basal and
TRAIL-induced IKKβ-NF-κB activation (Fig. 2A). More pro-
nounced inhibition of the basal NF-κB activity by sodium
arsenite could be achieved 6 h after treatment (see Figs. 3C andFig. 3 – Dose-dependent effects of sodiumarsenite for regulation
(A) Activation of ERK1/2, JNK,MAPK p38 and cJun 3 h after arsenite
STAT3, levels of TRAIL and TRAIL-R1 6 h after arsenite treatmen
(EMSA) by sodium arsenite 6 h after treatment. Free labeled prob
levels in WM9 cells 16 h after arsenite treatment. (E) NF-κB-Luc,
human TRAIL-promoter, TRAIL-R1-promoter and FLIP-promoter
reporter constructs with an additional (6 h) exposure to indicate
determined before and 6 h after treatment of WM9 cells with ars
and analyzed by the flow cytometry. Results of a typical experim
expression of TRAIL was determined before and 6 h after treatme
PE-labeledmAbs and analyzed by the flow cytometry. Results of a
(H) Suppression of arsenite-induced apoptosis by anti-TRAIL mA
30 min before sodium arsenite. For apoptosis analysis, cells wer
determined as percentage of cells with hypodiploid content of D4C). Since NF-κB controls expression of several genes encoding
anti-apoptotic proteins, such as cFLIP, XIAP, cIAP1/2, TRAF1/2
and Bcl-xL [16], arsenite-induced downregulation of NF-κB
activity may partially suppress an anti-apoptotic response of
cancer cells. As expected, we observed a downregulation of
cFLIP expression (for threemain isoforms) in LU1205 cells after
both arsenite alone and a combined treatment of arsenite and
TRAIL (Fig. 2B). Taken together, the effects of sodium arsenite
(inhibition of NF-κB activity, downregulation of cFLIP protein
levels and upregulation of surface TRAIL-R1/R2 levels) are
consistent with the observed increase in the susceptibility of
melanoma cells to TRAIL-mediated apoptosis (Figs. 1D and E).
Furthermore, TRAIL in combination with an inhibitor of
protein synthesis, cycloheximide (CHX; 2 μg/ml) (Fig. 2D), was
more effective for an induction of apoptosis than TRAIL alone,
probably due to a general inhibition of expression of short-
lived anti-apoptotic proteins, including cFLIP [42]. Taken
together, effects of sodium arsenite cotreatment were not
synergistic, but additive to TRAIL-induced apoptosis, andwere
compatible with the final levels of TRAIL-induced apoptosis in
the presence of CHX (Figs. 1E and 2D). As expected, zVAD-fmk
(5 μM), a universal caspase inhibitor, whichwas added into cell
cultures 30 min before treatment, strongly downregulated
levels of cell death, demonstrating a general dependence of
TRAIL-mediated cell death on caspase activities in many
melanoma lines, including WM9, OM431 and LU1205 cells
(Fig. 2E and data not shown). Furthermore, TRAIL-induced
apoptosis was efficiently suppressed by Ac-DEVD-CHO, a
caspase-3 inhibitor. Ac-IETD-CHO (5 μM), a caspase-8 inhibitor,
andAc-LEHD-CHO (5 μM), a caspase-9 inhibitor, provided some
protection against TRAIL-mediated apoptosis in WM9 and
LU1205 cells. In contrast, Ac-LEHD-CHO was not effective in
OM431 and SW1 cells with a deficiency in mitochondrial
pathway, probably due to a strong downregulation of basal
levels of apoptotic adaptor protein APAF1 (Figs. 2C and E).
These data were well correlated with the involvement of both
caspase-8 and caspase-9-mediated apoptotic pathways in the
response to TRAIL in some melanoma cell lines. However, it
also indicated that apoptotic death of melanoma cells with a
deficiency in themitochondrial pathway could be independent
of caspase-9 activity. In conclusion, metastatic melanoma
lines, WM9, LU1205, OM431 and SW1, responded to soluble
TRAIL by induction of apoptosis that could be additionally
increased with cotreatment either by CHX or by sodiumof cell signaling and gene expression inWM9melanoma cells.
treatment (Western blot analysis). (B) Total and active form of
t (Western). (C) Inhibition of NF-κB DNA-binding activity
e is not shown. (D) Western blot analysis of XIAP and cFLIP
Jun2-Luc, GAS-Luc (STAT-dependent) reporter activities, the
activities were determined 16 h after transient transfection of
d doses of arsenite. (F) Surface expression of TRAIL-R1 was
enite (2–6 μM). Cells were stained with PE-labeled mAbs
ent (one from three independent) are shown. (G) Surface
nt of WM9 cells with arsenite (4 μM). Cells were stained with
typical experiment (one from three independent) are shown.
b (5 μg/ml). Indicated mAbs were added into cell cultures
e stained by PI 48 h after treatment. Levels of apoptosis were
NA in the pre-G0/G1 region using flow cytometry.
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treatment byTRAIL in presence of CHXor arsenite still induced
low levels of apoptosis (data not shown) indicating a need for
different approaches for cell death induction.
Role of sodium arsenite treatment in the regulation of the
endogenous TRAIL, TRAIL-R1/R2 expression and
TRAIL-mediated apoptosis of melanoma cells
A potential role for soluble exogenous TRAIL as an inducer of
apoptosis in sensitive melanoma lines is quite well estab-
lished [11–13]. The next important questions are as follows: (1)What is the mechanism of endogenous surface expression of
TRAIL in TRAIL-R-positive melanomas that stimulates cell
death via paracrine actions? (2) What is the mechanism by
which sodium arsenite treatment affects levels of surface
expression of TRAIL-R? (3) What is the mechanism by which
sodium arsenite treatment affects endogenous cFLIP and XIAP
expression in melanoma cells?
Three major points of downstream signaling that have
profound effects on gene expression following sodium
arsenite treatment of WM9 melanoma cells are as follows: (i)
upregulation of the MAPK pathways [7,9] (Fig. 3A) that was
accompanied by an increase in Jun2-Luc reporter activity (Fig.
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suppression of the basal IKKβ activity [41] and the basal NF-κB
activity (Fig. 3C, EMSA; Fig. 3E, NF-κB-dependent transcrip-
tion); and (iii) inhibition of JAK2 activity, which was detected
by suppression of tyrosine phosphorylation of STAT3 (Fig. 3B)
and resulted in downregulation of STAT3-dependent GAS-Luc
reporter activity (Fig. 3E). Hence, arsenite treatment at low
doses (2–6 μM) was effective for downregulation of both NF-κB
and STAT3 activities, while the MAPK/JNK-cJun pathway was
substantially upregulated in WM9 melanoma cells in these
conditions.
Previous studies on the transcriptional regulation of the
endogenous TRAIL gene have demonstrated its control by NF-
κB and STAT3 in concert with several other transcription
factors, including SP1, AP1 and GATA [26,43]. Intracellular
TRAIL protein was easily detectable in WM9 melanoma cells
(Fig. 3B). However, TRAIL was not present on the cell surface of
nontreated melanoma cells (Fig. 3G). Determination of the
TRAIL promoter reporter activity (with high basal level inWM9
cells) demonstrated a relatively modest upregulation of this
activity 6 h after arsenite treatment (4 μM) (Fig. 3E). Further-
more, we observed the anticipated effects of NF-κB, AP1 and
STAT3 in the regulation of the TRAIL promoter activity in
melanomas. Super-stable IκBαΔN, which was a very effective
inhibitor of NF-κB, had a relatively small negative effect on the
TRAIL promoter. In contrast, pronounced inhibitory effects of
dominant-negative STAT3-F, JNK1-APF and TAM67 (dominant
negative form of cJun) have been observed. On the other hand,
permanently active variant, STAT3-C, was a powerful activa-
tor of the TRAIL promoter, as well as an active JNKK (MKK7-β1)
that was upstream of JNK. Simultaneously, permanently
active AKTmyr, which suppressed both JNK-cJun and STAT3
activation, also strongly suppressed the TRAIL promoter
activity (data not shown). These experimental data confirmed
that STAT3 and AP1/cJun are the main positive regulators of
the TRAIL transcription, while a role of NF-κB in this regulation
was relatively minor for melanoma cells.
Hence, due to strong activation of cJun (via MAPK/JNK), in
spite of the downregulation of STAT3 and NF-κB activities,
arsenite treatment actually increased the total TRAIL promoter
activity and TRAIL protein levels (Figs. 3B and E). Activating
effects of arsenite on TRAIL promoter and TRAIL protein level
were maximal at the dose 4 μM for WM9 cells (Fig. 3B).
Furthermore, arsenite (but not Bay7082, a standard IKK-NF-κB
suppressor) induced TRAIL expression on the cell surface,
indicating that this function was independent of NF-κB
inhibition (Fig. 3G). Arsenite treatment also upregulated sur-
face expression of TRAIL-R1/R2 in several melanoma lines,
including WM9 (Fig. 3F), in spite of the fact that TRAIL-R1 gene
promoter activity and total protein levels of TRAIL-R1 were
relatively stable in these conditions (Figs. 3B and E). These
results further suggested an effect of sodium arsenite on the
regulation of TRAIL-R1 protein trafficking to the cell surface.
Upregulation of TRAIL-R surface levels by arsenite treatment
was previously observed formultiplemyelomas [44] and some
leukemic cell lines [45].
Arsenite treatment of WM9 melanoma cells resulted in a
modest upregulation of both TRAIL and TRAIL-R1 surface
levels. Furthermore, a dramatic dose-dependent downregula-
tion of the cFLIP promoter activity and expression, as well asdownregulation of expression of XIAP, were also observed 16 h
after arsenite treatment (Figs. 3D, E). Importantly, expression
of both cFLIP and XIAP genes is known to be NF-κB dependent
[46]. Taken together, these arsenite-induced changesmay lead
to induction of apoptosis. Indeed, dose–response effects of
sodium arsenite on induction of caspase-3-dependent apop-
tosis were revealed in WM9 cells that could be suppressed by
anti-TRAIL mAb in cell culture (Fig. 3H and data not shown).
PARP cleavage (which could also be blocked with anti-TRAIL
mAb) served as an additional proof of caspase-3-dependent
mechanism of apoptosis in WM9 cells following indicated
treatments (data not shown). In summary, our data indicated
that for some melanoma lines (WM9, LU1205, SW1), arsenite
treatment by itself induced a modest TRAIL-mediated apop-
tosis 48 h after treatment based on surface expression of
TRAIL and TRAIL-R and paracrine induction of cell death.
However, it is more important to note that arsenite may also
effectively increase the susceptibility of melanoma cells to
exogenous TRAIL due to upregulation of surface TRAIL-R
levels and downregulation of cFLIP and XIAP.
WM9 metastatic melanoma cells are highly sensitive to
exogenous TRAIL, while LU1205 metastatic melanoma cells
are relatively resistant and require sodium arsenite or CHX
cotreatment to overcome this resistance. Nevertheless, many
effects of arsenite treatment on cell signaling pathways were
substantially similar in both cell lines: upregulation of the
MAPK/JNK-cJun pathway, downregulation of STAT3 andNF-κB
activation, which was accompanied by downregulation of
cFLIP levels (Figs. 3 and 4). Arsenite treatment also upregu-
lated TRAIL promoter activity, TRAIL protein levels and TRAIL
surface expression and increased levels of surface TRAIL-R2 in
LU1205 cells (Figs. 4A, D and E). However, at least two critical
parameters are different in LU1205 and WM9 cells: higher
basal levels of active AKT, due to PTEN dysfunction, and
higher levels of basal NF-κB activity in LU1205, compared to
WM9 cells [47,48]. These differences are well correlated with
substantially higher levels of the cFLIP promoter activity and
cFLIP protein expression in LU1205 cells (Figs. 4F and G), which
may explain their relative resistance to TRAIL.
Regulation of the cFLIP promoter activity and cFLIP expression in
melanoma cells
Expression of cFLIP and XIAP, which was known to be NF-κB
dependent [16,42,49], has been dramatically suppressed by
arsenite treatment (Figs. 3E, D and 4B, D). In order to more
precisely characterize the regulation of cFLIP/CFLAR expres-
sion, we used reporter constructs containing the human cFLIP
promoter [28,29]. In an addition to previously described cis-
elements, such as SP1- and cMyc-binding sites, this promoter
contains four putative AP1-binding sites, one putative CRE site
and two GAS sites that could bind STAT3, but no NF-κB-
binding sites (Fig. 5A). Using transient transfection of hFLIPpr-
Luc together with different expression constructs encoding
dominant-negative and permanently active forms of tran-
scription factors and corresponding kinases, we observed
dramatic activating effects of cJun-dominant-negative form
(TAM67) and strong inhibitory effects of active MEKK1 (as
MAP3K) and MKK7-β1 (as JNKK) on hFLIP promoter activity
(Fig. 5B). The effect of TAM67 on upregulation of protein levels
of cFLIP was relatively transient and was quickly followed by
Fig. 4 – Regulation of cell signaling and gene expression by sodium arsenite in LU1205 melanoma cells. (A) Activation of
ERK1/2 and cJun 3 h after arsenite treatment (Western blot analysis). Inhibition of STAT3 activity, levels of TRAIL and TRAIL-R1
and R2 6 h after arsenite treatment (Western). (B) Western blot analysis of cFLIP levels 16 h after arsenite treatment.
Dave-2 mAb to FLIP was used. (C) Inhibition of NF-κB DNA-binding activity (EMSA) by sodium arsenite 6 h after treatment.
(D) The human TRAIL- and FLIP-promoter activities were determined 16 h after transient transfection of reporter constructs
with an additional (6 h) exposure to indicated doses of arsenite. (E) Surface expression of TRAIL and TRAIL-R2 was determined
before and 6 h after treatment of LU1205 cells with arsenite (4 μM). Cells were stained with correspondent PE-labeled mAbs
and analyzed by the flow cytometry. Results of a typical experiment (one from three independent) are shown. (F) Normalized
basal levels of the hFLIP promoter activities in indicated melanoma lines; pGL3-basic—the empty vector. Error bars
represent mean±SD from three independent experiments. (G) The basal protein levels of cFLIP in indicated melanoma lines
determined by Western blot analysis. Monoclonal Ab to FLIP (Dave-2) was used.
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Fig. 5 – The cFLIP promoter analysis. (A) Putative transcription factor-binding sites of the human cFLIP/CFLAR gene promoter.
Position of binding sites on the human chromosome-2 is indicated. (B) Transient transfection of hFLIPpr-Luc and expression
vectors encoding indicated dominant-negative and permanently active forms of proteins in the presence of β-gal
expression construct (at a plasmid DNA ratio 1:3:0.5) into WM9 cells. Normalized luciferase activity was determined 16 h after
transfection. (C) Effects of dominant-negative form of cJun (TAM67) on cFLIPL expression levels (determined by Western blot
analysis) after transient transfection ofWM9 cells. (D, E) Effects of specific inhibitors: of theMEK-ERK pathway, U0126 (10μM), of
JNK, SP600125 (20 μM), of the PI3K-AKT pathway, LY294002 (20 μM) on hFLIPpr-Luc activity in transiently transfected WM9
and LU1205 melanoma cells. Arsenite (As, 4 μM) was used. Cells were treated for 6 h before determination of normalized
luciferase activity.
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The effects of TAM67 were well correlated with a strong
increase in cFLIP promoter activity after inhibition of JNK
activation by specific pharmacological inhibitor SP600125(Figs. 5D and E), while the presence of arsenite dramatically
diminished this effect. The effect of U0126, a MEK-ERK
inhibitor, was less pronounced in both WM9 and LU1205
cells. In contrast, STAT3 expression constructs (both active
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well as super-stable IκBΔN had no real effects on the FLIP
promoter (Fig. 5B). However, since FLIP protein levels are
known to be NF-κB-dependent based on several studies
[42,49], it probably indicated an indirect relationship, which
could be mediated by the product of another NF-κB-regulated
gene. In this regard, the COX-2 gene that is permanently
active in melanomas [48] and is under direct control of NF-κB
[50] is a possible candidate. A detailed characterization of
human FLIP promoter and regulation of cFLIP gene expression
are still in progress. In summary, the negative effects of
arsenite treatment on cFLIP promoter activity are mediated
by MAPK/JNK-cJun pathways. Interestingly, a recent study
has described a JNK-mediated protein degradation of cFLIP
via activation of the E3 protein ligase Itch [51], confirming the
important role of MAPK/JNK in the regulation of FLIP
expression at the different control points.
In order to further confirm a critical role of cFLIP down-
regulation for accelerating TRAIL-mediated apoptosis in
human melanomas, we created several cFLIP RNAi constructs
(based on Oligoengine-developed strategy), FLIP-92 RNAi
construct effectively suppressed cFLIPL and cFLIPs expression
in LU1205 (Fig. 6A), OM431 and SW1 melanomas (data not
shown). We used two different mAbs to human cFLIP: Dave-2
(I) and NF6 (II) (Fig. 6A). BothmAbs detected downregulation of
cFLIPL expression following RNAi-mediated suppression;
furthermore, NF6 mAb also detected a decrease in cFLIPs
levels, while Dave-2 mAb was not able to efficiently detect the
short form of FLIP neither in control cells nor in FLIP-RNAi-
transfected cells after puromycin-based selection. RNAi-
mediated reduction of cFLIP expression substantially upregu-
lated TRAIL- or (TRAIL and CHX)-induced apoptosis of control
LU1205, OM431 and SW1 cells but did not affect levels of
arsenite-induced apoptosis because arsenite by itself was in-
volved in the inhibition of cFLIP (Figs. 6B, C and data not
shown).
COX-2 suppression downregulates cFLIP levels and accelerates
TRAIL- and FasL-mediated apoptosis in human melanomas
The COX-2-cFLIP-positive axis was recently described for
some cell systems [52] and it is likely to be true in
melanomas as well, where both COX-2 and cFLIP are
permanently active. We suppressed COX-2 expression in
LU1205 and WM9 cell lines using several COX-2 RNAi
expressing constructs: COX-2-379 RNAi was the most effec-
tive. It was also accompanied by a pronounced suppression
of both cFLIPL and cFLIPs (Fig. 6D). Effects of the COX-2–
prostaglandin-E2 signaling pathway on cFLIP expression were
mediated via upregulation of the cFLIP promoter activity
since suppression of COX-2 downregulated the cFLIP promo-
ter activity (Fig. 6E). In contrast, we did not observe
pronounced effects of COX-2 suppression on TRAIL promoter
activity (Fig. 6E) or total TRAIL levels (data not shown). In
summary, COX-2 suppression notably increased levels of
TRAIL- or (TRAIL+CHX)-induced apoptosis in LU1205 cells
(Fig. 6F). The inhibitory effects of COX-2 on JNK-cJun activities
[53] may be involved in downregulation of cFLIP levels
following suppression of COX-2 by specific RNAi.
Furthermore, COX-2 suppression by specific RNAi
decreased levels of surface expression of TRAIL after arsenitetreatment of LU1205 melanoma cells (Figs. 7A and B),
indicating a possible role of COX-2 in the regulation of TRAIL
protein translocation to the cell surface. Unexpectedly, the
effect of COX-2 suppression combined with arsenite on TRAIL
surface expression was the reverse to the previously observed
upregulation of FasL surface expression in these conditions
[48]. However, arsenite-induced apoptosis of melanoma cells
with suppressed COX-2 was dramatically increased. Pretreat-
mentwithmonoclonal antibodies against FasL, TRAIL or TNFα
demonstrated that this increase was mainly due to FasL-
mediated death signaling; however, TRAIL-mediated death
was still involved (Fig. 7C). Taken together, COX-2 down-
regulation was determined as a powerful tool for upregulation
of arsenite-induced apoptosis of human melanoma through
both FasL-Fas and TRAIL-TRAIL-R pathways with simulta-
neous cFLIP suppression.
Downregulation of TRAIL-R surface expression by AKT
suppresses TRAIL-mediated apoptosis in melanoma
The PI3K-AKT pathway, which controls and coordinates many
survival functions in the cell (including high basal COX-2
levels), may suppress arsenite-induced sensitization to TRAIL-
mediated apoptosis [54]. In contrast, suppression of the PI3K-
AKT pathway by specific inhibitor LY294002 may additionally
increase levels of (TRAIL+CHX)-induced apoptosis of human
melanoma cells (Fig. 7E). The total effects of LY294002 (50 μM)
cotreatment on TRAIL-induced cell death were even more
pronounced due to relatively high levels of necrotic death in
treated melanoma cells in these conditions (Fig. 7E and data
not shown). High levels of the secondary necrotic cells
(PI-positive, Annexin-V-negative) have been observed even
12 h after TRAIL treatment in the presence of LY294002 (Fig.
7D). TRAIL-induced death of mouse metastatic melanoma
cells was also substantially increased in the presence of
LY294002 (see Fig. 8C).
In these experiments, we used previously established
mouse SW1 melanoma cells stably transfected either with
the empty vector or with the construct expressing perma-
nently active AKTmyr [55]. Overexpression of active AKT
caused downregulation of AP1- and STAT3-dependent tran-
scription and modest upregulation of NF-κB activity and NF-
κB-dependent transcription (Figs. 8A, B and data not shown).
The general transcriptional changes induced by AKT over-
activation resulted in upregulation of the Fas promoter activity
[55], while the FasL promoter activity [56], as well as the TRAIL
promoter and TRAIL-R1 promoter activities, was notably
downregulated (Fig. 3F and data not shown). Correspondingly,
Western blot analysis demonstrated a strong decrease in
endogenous protein level of TRAIL, FasL and modest decrease
in total TRAIL-R1 protein levels in AKTmyr-transfected cells
(Fig. 8A). Furthermore, surface expression of TRAIL-R1 was
substantially decreased in AKTmyr-transfected cells, even
less in the presence of arsenite, revealing a critical level of
decreased sensitivity to TRAIL in these cells (Fig. 8D). Indeed,
there was a substantially downregulated sensitivity to apop-
totic signaling induced by soluble exogenous TRAIL or by a
combination of TRAIL and CHX in AKT-transfectedmelanoma
cells (Fig. 8C). This was in the contrast to increased sensitivity
to exogenous FasL, which was previously observed in these
cells [55]. AKT-mediated upregulation of COX-2 levels and
Fig. 6 – Suppression of cFLIP expression by cFLIP-RNAi or COX2-RNAi accelerates TRAIL-mediated apoptosis of melanoma
cells. (A) Western blot analysis of cFLIP levels in LU1205 cells stably transfected with the empty vector pSR-puro or with RNAi
cFLIP-92. Long and short form of cFLIP are indicated. Monoclonal Ab to FLIP (clone NF6) (II) was used. (B, C) Levels of
apoptosis were determined 40 h after indicated treatment of LU1205 and OM431 cells stably transfected with the empty vector
or RNAi cFLIP-92. Error bars represent mean±SD from three independent experiments. (D) Suppression of COX-2 expression
by COX-2 RNAi downregulates cFLIP levels. Western blot analysis of COX-2 and cFLIP levels (with two types of mAbs
against cFLIP, Dave-2 and NF6) in LU1205 cells stably transfected with the empty vector pSR-puro or RNAi COX2-379. Twomain
protein bands of COX2 (p72 and glycosylated form p75) are indicated. (E) Effects of RNAi COX2-379 on hFLIP- and
hTRAIL-promoter activities. LU1205 cells were transiently transfected with hFLIP-Luc, pSR-puro and β-gal (1:3:0.5) or with
hFLIP-Luc, RNAi COX-2 and β-gal (1:3:0.5). Normalized Luc activity was determined 16 h after transient transfection.
(F) Apoptosis levels in LU1205 cells stably transfected with the empty vector pSR-puro or RNAi COX2-379 40 h after treatment
with soluble TRAIL (50 ng/ml) or TRAIL+CHX (2 μg/ml).
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additional survival signaling in these cells (Figs. 8A and B).
Taken together, our results confirmed a protective role
of AKT against TRAIL-induced apoptosis of melanoma incell culture conditions. The next question to be addressed
was melanoma growth in vivo after injection of the control
(transfected by the empty vector) SW1 melanoma cells and
AKTmyr-transfected SW1 cells into its natural host, C3H/
Fig. 7 – Effects of COX-2 and PI3K-AKT suppression on arsenite- and TRAIL-induced apoptosis in melanoma cells. (A) LU1205
cells stably transfectedwith the pSR-puro orwith RNAi COX2-379were treated for 6 hwith arsenite (4μM). COX-2 protein levels
were detected by Western blot analysis. (B) Surface TRAIL levels in LU1205-puro and LU1205/COX-2 RNAi stably transfected
cells before (control) and after arsenite treatment. (C) Effects of pretreatment with anti-FasL or anti-TRAIL mAb (5 μg/ml) on
apoptosis induced by arsenite (4 μM) treatment. Error bars represent mean±SD from three independent experiments.
(D) LU1205 cells were stained by Annexin-V-FITC and PI 12 h after indicated treatment. (E) LU1205 and OM431 cells were treated
by TRAIL+CHX 48 h with or without LY294002 (LY, 50 μM). Apoptosis levels were determined as percentage of cells with
hypodiploid content of DNA in the pre-G0/G1 region using flow cytometry. Error bars represent mean±SD from three
independent experiments.
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apoptotic responses of SW1 cells revealed a substantial
downregulation of tumor growth [57]. In contrast, the effectof AKT overexpression in melanoma was a dramatic
acceleration of tumor growth in mice (Figs. 8E–G). This
was likely the result of AKT-mediated positive control of
Fig. 8 – AKTmyr overexpression downregulates TRAIL-mediated apoptosis of SW1 melanoma cells and dramatically
accelerates SW1 melanoma transplant growth in vivo. (A) Western blot analysis of indicated proteins in SW1 melanoma cells
stably transfected with the empty vector or AKTmyr expression construct. (B) Effects of AKTmyr on NF-κB DNA-binding activity
determined by EMSA. (C) Overexpression of AKTmyr downregulated TRAIL-, (TRAIL+CHX)- and (TRAIL+CHX+LY)-induced
apoptosis of SW1 cells . (D) Surface TRAIL-R1 levels in SW1 cells stably transfected with the empty vector (puro) or AKTmyr
expression construct before and after arsenite treatment. Cell were stained with anti-TRAIL-R1 mAb and analyzed by the flow
cytometry. Results of typical experiment (one from three independent) are shown. (E–G) SW1 melanoma cells, permanently
transfected with the empty vector or with AKTmyr expression construct, were injected subcutaneously into C3H/HEJ mice
(ten mice for each group), and tumor growth was monitored during the next three weeks. TS—relative tumor size.
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sion of TRAIL-mediated signaling due to downregulation of
TRAIL-R1 surface expression (Fig. 8D). This protects mela-nomas from targeting by TRAIL-producing natural killer
cells and cytotoxic T lymphocytes, thus facilitating tumor
development.
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Arsenic (as arsenic trioxide or sodium arsenite) is a potent
inducer of apoptosis for many types of cancer, including
acute promyelocytic leukemias [4], prostate cancer [5] and
some types of melanomas [7]. An important feature of
arsenic treatment is the quite narrow window of concentra-
tions (1–10 μM) when this agent may induce apoptosis by
change in the pattern of specific gene expression. At higher
doses of arsenite (>10 μM), strong necrosis starts to
substitute apoptosis of cancer cells, diminishing usefulness
of this treatment. Two critical enzyme targets, which are
suppressed by arsenite treatment, are IKKβ [41] and JAK2 [58].
Inhibition of these enzymes results in a suppression of the
NF-κB and STAT3-mediated signaling, which downregulates
gene expression of cFLIP, XIAP, cIAP and BclxL [2,59], proteins
involved in the regulation of anti-apoptotic protection in the
cell (Fig. 9). On the other hand, stimulation of growth factor
receptors by arsenite accelerates the MAPK/JNK signaling
pathways [9,60] that activates cJun, cFos and ATF2 transcrip-
tion factors, which control transcription of both TRAIL and
TRAIL-R1/R2 genes [26,27] (see Fig. 9). Finally, activation of
Rac1 and Rac1-NADPH oxidase activity by sodium arsenite
initiates a massive production of ROS in cells [61], which is
followed by oxidative stress [62], mitochondrial dysfunction
and an induction of mitochondrial death pathway in someFig. 9 – A schematic illustration of the principal signaling pathw
Arsenite accelerates activation of the MAPK pathways at the EGF
correspondent transcription factors of the AP-1 family: ATF2, c-Fo
signaling pathways and downregulates expression of STAT3- an
of the arsenic effects is linked with Rac1-NADPH oxidase activat
genotoxic stress and initiation of the mitochondrial death pathw
preferentially plays a role of the regulator of cell signaling and ge
cell surface TRAIL and its receptor-1 and receptor-2. This creates
pathway via paracrinemechanism and dramatically increases a s
See additional explanation and references in the text.melanoma lines. In addition, subsequent genotoxic stress also
occurs, as well as an upregulation of p53 protein levels and
p53-dependent gene expression, such as BAX and TRAIL-R2
[39,63–65], which is accompanied by an increase in apoptosis
and secondary necrosis. Furthermore, levels of necrotic death
are dramatically increased at arsenite doses higher than
10 μM. Arsenite also affects cytoskeleton functions and
promotes TRAIL-R1/R2 translocation from the intracellular
pools to cell surface, as it was observed in the present study.
The existence of intracellular pools of TRAIL-R1/R2 and a
suppression of receptor translocation in some cancer cell lines
have been previously described in several publications [66,67].
Surprisingly, many cell types (both normal and cancer) are
relatively resistant to cytotoxic effects of low doses of sodium
arsenite, thereby making it possible to use this agent as a
regulator of cell signaling pathways in different types of
combined treatment. Indeed, our previous [7] and current
studies indicate that most melanoma are relatively resistant
to arsenite treatment (1–10 μM) and, at best, may develop a
modest TRAIL-mediated apoptosis. However, arsenite
induced profound changes of susceptibility of melanoma to
exogenous recombinant TRAIL by upregulation of TRAIL-R1
and R2 surface expression and JNK-cJun-mediated down-
regulation of cFLIP levels. Published reports indicate that
myeloma cells display synergistic activation of TRAIL-
mediated apoptosis by arsenic [44,45]. However, we observed
largely additive effects of such combined treatment. Never-ays that are affected by sodium arsenite (As) treatment.
R that finally upregulates MAPK p38, ERK and JNK and the
s, c-Jun. Arsenite suppresses the JAK2-STAT3 and IKK-NF-κB
d NF-κB-dependent anti-apoptotic genes. The third direction
ion, production ROS (superoxide), induction oxidative and
ay in some melanoma lines. At low doses (1–10 μM), arsenite
ne expression, inducing expression and translocation to the
conditions for an induction of the TRAIL-mediated death
usceptibility of arsenite-treated cells to the exogenous TRAIL.
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apoptosis, which has been demonstrated for some types of
tumors, including melanomas. Many attempts have been
made to increase a sensitivity of cancer cells to TRAIL using
natural or pharmacological inhibitors of NF-κB, STAT3, AKT
and COX-2 [46]. Mechanistically, given that arsenite inhibits
NF-κB and STAT3 activation [7,41], this agent may be an
effective inhibitor of cancer cell survival when used in
combination with recombinant TRAIL, as was observed in
the present study.
Numerous investigations performed on different types of
cancer cells established anti-apoptotic role of both forms of
cFLIP (cFLIPs and cFLIPL) in TRAIL- and FasL-mediated
apoptosis [13,14,18,19]. However, cFLIPL may perform antag-
onistic functions in the cell since its expression at lower
levels actually supported caspase-8 activation and cell death
[20]. In the present study, we further confirmed anti-
apoptotic role of cFLIPL in melanomas, including melanoma
cells with a deficiency of the mitochondrial death pathway
(such as OM431 and SW1), and demonstrated that arsenite
treatment dramatically downregulated cFLIP promoter activ-
ity and expression via negative regulation by the JNK-cJun
pathway. A recent study has described a JNK-mediated
protein degradation of cFLIPL through activation of the E3
protein ligase Itch [51], confirming the important role of
MAPK/JNK in the regulation of cFLIPL protein stability.
NF-κB-dependent control of cFLIP expression [42,49]
appeared to be indirect (because the cFLIP promoter has no
functional κB sites) and may be based on NF-κB-dependent
expression of COX-2 [50], which, in turn, may inhibit JNK and
positively regulate cFLIP promoter activity. However, the COX-
2–prostaglandin E2 pathway possess multiple targets in the
cell, in addition to regulation of cFLIP expression. COX-2
suppression dramatically increased sensitivity to sodium
arsenite treatment in human melanomas due to both cFLIP
downregulation and upregulation of surface expression FasL
[48], increasing levels of FasL-mediated apoptosis.
Finally, the PI3K-AKT pathway that operates at many
levels of cell survival is involved in the positive regulation of
NF-κB, COX-2 [54] and negative regulation of TRAIL [68] and
TRAIL-R surface expression in melanomas, as we observed in
the present study. On the other hand, treatment of mela-
noma cells with TRAIL in combination with the inhibitor of
the PI3K-AKT pathway LY204002 substantially increased
levels of cell death, especially necrotic death. In spite of the
close similarity in the induction of death signaling via Fas
and TRAIL-R pathways, there were remarkable differences in
the regulation of expression and intracellular trafficking of
endogenous FasL and TRAIL. One of these features was
opposite effects of COX-2 suppression on arsenite-induced
changes in TRAIL and FasL surface expression. A more
complete understanding of the mechanism behind such
differences will permit more accurate choice for induction
of apoptosis in cancer cells.
In summary, finding regulators of cell signaling with
opposite effects on the promoter activity of TRAIL and cFLIP
is an intriguing prospect aim. In this respect, our investigation
that JNK-cJun serves as a negative regulator of cFLIP and a
positive regulator of TRAIL expression may open new possi-
bilities in the anticancer therapy.Acknowledgments
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